Circumvent™ PCV vaccine - new PCV2 vaccine license
16 October 2007
Millsboro, Delaware
Circumvent™ PCV vaccine - new PCV2 vaccine license
Intervet receives full USDA license for first two-dose Porcine Circovirus, Type 2 vaccine
MILLSBORO, Del. (Oct.16, 2007) – Intervet Inc. announces the full USDA license for Circumvent™ PCV (Porcine Circovirus Vaccine, Type 2, Killed Baculovirus Vector), which provides a superior solution for the control and management of Porcine Circovirus Associated Disease (PCVAD). The vaccine is labelled as “For use in healthy swine, 3 weeks of age or older, as an aid in the prevention of viremia and as an aid in the prevention of virus shedding caused by Porcine Circovirus.” Under field conditions, with tens of millions of doses used to date, the
vaccine has been shown to reduce mortality substantially and of equal or greater importance to provide consistently superior growth performance through processing versus non-vaccinates.
Circumvent PCV can be used in pigs as early as three weeks of age. For optimal immune response pigs should receive two 2 cc (millilitre) doses given through intramuscular injection three weeks apart, with vaccinations suggested at three and six weeks of age.
“This vaccine has proven effective in field studies to significantly reduce mortality, morbidity and medication costs, while improving growth performance versus non-vaccinates,” says John Foxx, Intervet Marketing Manager.
Circumvent PCV was the first PCV2 vaccine to receive a USDA license, obtaining its conditional license in October 2005. A limited supply of the vaccine was made available to veterinarians beginning in April 2006. Due to unexpected demand manufacturing scale-up activities continued into 2007 when significant quantities of the vaccine started becoming available.
While single-dose vaccines may reduce mortality from PCVAD, the Circumvent two-dose regimen helps reduce morbidity, and allow pigs to maintain normal growth performance in addition to reducing mortality. Field studies involving Circumvent PCV vaccination at 3 and 6 weeks of age indicate that improved growth metrics in vaccinates versus controls may prove more economically significant for producers than the reduction in mortality. Circumvent PCV contains Microsol Diluvac Forte® (MDF) adjuvant, a highly effective dual adjuvant proven safe in millions of vaccinates. MDF has been proven effective and safe over several years in other Intervet vaccines, such as End-FLUence® 2 and MycoSilencer® ONCE.
In efficacy studies conducted by Intervet Inc. for licensure, vaccination with Circumvent PCV was shown to prevent PCV2 viremia (virus in the blood) as well as nasal and fecal shedding in a dual challenge model (PCV2 and PRRS) while PCV2 challenged controls were 100% positive.
“The North American swine industry has vaccinated millions of pigs with Circumvent PCV and the consensus is that it is a highly efficacious and cost effective vaccine,” says Foxx.
About Intervet
Intervet Inc. (www.intervetusa.com) is an affiliate of Intervet International B.V., the world’s leading
manufacturer of veterinary vaccines and currently ranked third among global animal health suppliers. The
company is a leader in research and dedicated to the development, production and marketing of
innovative, high-quality animal-health products. Intervet International B.V. currently employs
approximately 5,000 personnel and maintains a global distribution network of subsidiary companies and
agents in 120 countries. End-FLUence, Myco Silencer and Diluvac Forte are registered trademarks
and Circumvent is a trade mark of Intervet Inc. or an affiliate. © 2007 Intervet Inc. All rights reserved.
###
For more information, contact:
John Foxx, (302) 934-4366, or
john.foxx@Intervet.com
Tyler Kelley, 816-410-5152, or
kelleyt@osborn-barr.com
